Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Ratio (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Equity Ratio for 16 consecutive years, with 0.86 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 69.62% to 0.86 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.86 through Dec 2025, up 69.62% year-over-year, with the annual reading at 0.86 for FY2025, 69.62% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.86 at Gyre Therapeutics, up from 0.64 in the prior quarter.
  • The five-year high for Equity Ratio was 8.56 in Q3 2023, with the low at 0.12 in Q4 2023.
  • Average Equity Ratio over 5 years is 1.6, with a median of 0.84 recorded in 2021.
  • The sharpest move saw Equity Ratio skyrocketed 804.18% in 2023, then plummeted 90.82% in 2024.
  • Over 5 years, Equity Ratio stood at 1.07 in 2021, then dropped by 20.24% to 0.85 in 2022, then tumbled by 85.95% to 0.12 in 2023, then surged by 321.84% to 0.5 in 2024, then skyrocketed by 69.62% to 0.86 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.86, 0.64, and 0.85 for Q4 2025, Q3 2025, and Q2 2025 respectively.